Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients

Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients

Background: Immunocompromised populations, especially cancer patients, rely on the effectiveness of the COVID-19 vaccines to protect against severe infection or death, both against the original wild-type (WT) SARS CoV-2 virus and its many variants that have emerged. Methods: We conducted a study usi...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher W. Dukes, Junmin Whiting, Qianxing Mo, Christopher L. Cubitt, Barbara J. Kuter, Brett Leav, Kayoko Kennedy, Julie Rathwell, Shari Pilon-Thomas, Anna R. Giuliano
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Vaccine: X
Subjects:
SARS-CoV-2
COVID-19
SARS-CoV-2 variant
cancer patient
Neutralizing antibodies
MSD competitive binding assay
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136225000725
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2590136225000725

Similar Items